The type of adjuvant strongly influences the T-cell response during nanoparticle-based immunization

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 1, 2014, Pages 164-169

  Knuschke, Torben ^a   Epple, Matthias ^b   Westendorf, Astrid M ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Calcium phosphate; Influenza virus; Nanoparticles; T cell immunity; Vaccine

Indexed keywords

BACTERIAL VACCINE; CALCIUM PHOSPHATE; CYTOKINE; DOUBLE STRANDED RNA; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; NANOPARTICLE; OLIGONUCLEOTIDE; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL INFECTION; BIODEGRADABILITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CPG ISLAND; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENTIATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION CONTROL; INFLUENZA; INNATE IMMUNITY; LYMPHOCYTE COUNT; NONHUMAN; PROTEIN EXPRESSION;

EID: 84896713886     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26203     Document Type: Article

References (27)

1. De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine 2008; 3:133-49; PMID:18686775; http://dx.doi.org/10. 2147/IJN.S596
2. Diwan M, Elamanchili P, Cao M, Samuel J. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr Drug Deliv 2004; 1:405-12; PMID:16305402; http://dx.doi.org/10.2174/1567201043334597
3. Wilson KD, de Jong SD, Tam YK. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Adv Drug Deliv Rev 2009; 61:233-42; PMID:19232375; http://dx.doi.org/10.1016/j.addr.2008.12.014
4. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811; PMID:10837075; http://dx.doi.org/10.1146/annurev.immunol.18.1.767
5. Klinman DM, Ishii KJ, Gursel M, Gursel I, Takeshita S, Takeshita F. Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. Drug News Perspect 2000; 13:289-96; PMID:12937643
6. Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009; 61:248-55; PMID:19272313; http://dx.doi.org/10.1016/j.addr.2008.12.012
7. Stahl-Hennig C, Eisenblätter M, Jasny E, Rzehak T, Tenner-Racz K, Trumpfheller C, Salazar AM, Uberla K, Nieto K, Kleinschmidt J, et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 2009; 5:e1000373; PMID:19360120; http://dx.doi.org/10.1371/journal.ppat.1000373
8. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006; 442:39-44; PMID:16823444; http://dx.doi.org/10.1038/nature04946
9. Robbins MA, Rossi JJ. Sensing the danger in RNA. Nat Med 2005; 11:250-1; PMID:15746933; http://dx.doi.org/10.1038/nm0305-250
10. Sokolova V, Knuschke T, Kovtun A, Buer J, Epple M, Westendorf AM. The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomaterials 2010; 31:5627-33; PMID:20417963; http://dx.doi.org/10. 1016/j.biomaterials.2010.03.067
11. Knuschke T, Sokolova V, Rotan O, Wadwa M, Tenbusch M, Hansen W, Staeheli P, Epple M, Buer J, Westendorf AM. Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J Immunol 2013; 190:6221-9; PMID:23667109; http://dx.doi.org/10.4049/ jimmunol.1202654
12. Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines 2011; 10:539-50; PMID:21506650; http://dx.doi.org/10.1586/erv.11.21
13. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 2008; 364:272-80; PMID:18555624; http://dx.doi.org/10.1016/j.ijpharm.2008.04.036
14. Kozlova D, Chernousova S, Knuschke T, Buer J, Westendorf AM, Epple M. Cell targeting by anti-body-functionalized calcium phosphate nanoparticles. J Mater Chem 2012; 22:396-404; http://dx.doi.org/10.1039/c1jm14683a
15. Sokolova V, Knuschke T, Buer J, Westendorf AM, Epple M. Quantitative determination of the composition of multi-shell calcium phosphate- oligonucleotide nanoparticles and their application for the activation of dendritic cells. Acta Biomater 2011; 7:4029-36; PMID:21784177; http://dx.doi.org/10.1016/j.actbio.2011.07.010
16. Sokolova V, Kozlova D, Knuschke T, Buer J, Westendorf AM, Epple M. Mechanism of the uptake of cationic and anionic calcium phosphate nanoparticles by cells. Acta Biomater 2013; 9:7527-35; PMID:23454056; http://dx.doi.org/10. 1016/j.actbio.2013.02.034
17. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 2005; 298:315-22; PMID:15961266; http://dx.doi.org/10.1016/j.ijpharm. 2005.03.035
18. Zwiorek K, Bourquin C, Battiany J, Winter G, Endres S, Hartmann G, Coester C. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm Res 2008; 25:551-62; PMID:17912489; http://dx.doi.org/10.1007/s11095-007-9410-5
19. Kerkmann M, Lochmann D, Weyermann J, Marschner A, Poeck H, Wagner M, Battiany J, Zimmer A, Endres S, Hartmann G. Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles. Oligonucleotides 2006; 16:313-22; PMID:17155907; http://dx.doi.org/10.1089/oli. 2006.16.313
20. Zolnik BS, González-Fernández A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology 2010; 151:458-65; PMID:20016026; http://dx.doi.org/10.1210/en.2009-1082
21. Mottram PL, Leong D, Crimeen-Irwin B, Gloster S, Xiang SD, Meanger J, Ghildyal R, Vardaxis N, Plebanski M. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm 2007; 4:73-84; PMID:17274665; http://dx.doi.org/10.1021/mp060096p
22. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-93; PMID:8893001; http://dx.doi.org/10.1038/ 383787a0
23. Brown DM, Dilzer AM, Meents DL, Swain SL. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 2006; 177:2888-98; PMID:16920924
24. Papi A, Stanciu LA, Papadopoulos NG, Teran LM, Holgate ST, Johnston SL. Rhinovirus infection induces major histocompatibility complex class I and costimulatory molecule upregulation on respiratory epithelial cells. J Infect Dis 2000; 181:1780-4; PMID:10823784; http://dx.doi.org/10.1086/315463
25. de Jong EC, Vieira PL, Kalinski P, Schuitemaker JH, Tanaka Y, Wierenga EA, Yazdanbakhsh M, Kapsenberg ML. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J Immunol 2002; 168:1704-9; PMID:11823500
26. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3:849-54; PMID:9256274; http://dx.doi.org/10.1038/nm0897-849
27. Hafner AM, Corthésy B, Merkle HP. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Adv Drug Deliv Rev 2013; PMID:23751781; http://dx.doi.org/10.1016/j.addr.2013.05.013